Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Endocrine tumors, also referred to as neuroendocrine tumors (NETs), are defined by a common phenotype which is characterized by the expression of general markers (neuron specific enolase, chromogranin, synaptophysin) and hormone secretion products. These tumors may be localized in any part of the body and are generally discovered in non-specific situations, i.e. not immediately suggestive of NETs (tests for inherited predisposition to tumors or for a clinical syndrome caused by abnormal hormone secretion).
Biomarker and diagnostic research for neuroendocrine neoplasm has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
268 clinical trials registered, 53 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 5 PHASE4, 20 PHASE3, 79 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06607692](https://clinicaltrials.gov/study/NCT06607692) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). |
PHASE1 |
Fundación de investigación HM |
RECRUITING |
[NCT04907643](https://clinicaltrials.gov/study/NCT04907643) | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | NA | Cedars-Sinai Medical Center | RECRUITING |
[NCT07357623](https://clinicaltrials.gov/study/NCT07357623) | Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors | PHASE2 | Shanghai Chest Hospital | RECRUITING |
[NCT07439757](https://clinicaltrials.gov/study/NCT07439757) | AI-Powered Precision Decision-Making for Pancreatic Diseases | — | Changhai Hospital | RECRUITING |
[NCT07129252](https://clinicaltrials.gov/study/NCT07129252) | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | PHASE1 | Crinetics Pharmaceuticals Inc. | RECRUITING |
408 publications have been identified in PubMed for neuroendocrine neoplasm. Research spans Review / Meta-Analysis (23%), Case Report / Case Series (23%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 95 | 23% |
Patient case studies | 95 | 23% |
Disease patterns and progression | 51 | 13% |
Testing and diagnosis research | 49 | 12% |
Laboratory research | 45 | 11% |
Clinical study results | 39 | 10% |
Other research | 23 | 6% |
New treatment approaches | 11 | 3% |
Zuber E (2026). [PMID: 41612703](https://pubmed.ncbi.nlm.nih.gov/41612703/). *J Vet Diagn Invest*. [Case Report / Case Series]
Pu T (2026). [PMID: 41526627](https://pubmed.ncbi.nlm.nih.gov/41526627/). *Ann Surg Oncol*. [Clinical Trial Publication]
Asmar C (2026). [PMID: 41547118](https://pubmed.ncbi.nlm.nih.gov/41547118/). *Cancer Epidemiol*. [Diagnostic / Biomarker]
Mete O (2026). [PMID: 41432735](https://pubmed.ncbi.nlm.nih.gov/41432735/). *Virchows Archiv : an international journal of pathology*. [Basic Science / Preclinical]
Steinl G (2026). [PMID: 41747493](https://pubmed.ncbi.nlm.nih.gov/41747493/). *Surg Oncol*. [Epidemiology / Natural History]
Kawakubo N (2026). [PMID: 41213650](https://pubmed.ncbi.nlm.nih.gov/41213650/). *J Adolesc Young Adult Oncol*. [Epidemiology / Natural History]
Zhao K (2026). [PMID: 41955177](https://pubmed.ncbi.nlm.nih.gov/41955177/). *Neuroendocrinology*. [Epidemiology / Natural History]
Budzich-Napiwodzka M (2026). [PMID: 41686192](https://pubmed.ncbi.nlm.nih.gov/41686192/). *Pol Arch Intern Med*. [Diagnostic / Biomarker]
Shimura M (2026). [PMID: 42053775](https://pubmed.ncbi.nlm.nih.gov/42053775/). *Clin J Gastroenterol*. [Case Report / Case Series]
Haque MZ (2026). [PMID: 42052308](https://pubmed.ncbi.nlm.nih.gov/42052308/). *Clin Case Rep*. [Diagnostic / Biomarker]
AI-curated news mentioning neuroendocrine neoplasm
Updated May 25, 2026
PharmaEssentia will present new clinical data on Ropeginterferon Alfa-2b for essential thrombocythemia at upcoming ASCO and EHA conferences in 2026. This data may provide insights into the drug's efficacy and safety profile for patients with this condition.
FDA approves ScinoPharm Taiwan’s glatiramer acetate injection for relapsing multiple sclerosis, marking the first complex injectable generic approval for this therapy. Additionally, Alkermes receives breakthrough therapy designation for alixorexton, an oral treatment for narcolepsy type 1.